Trial Profile
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of LY2922470 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2922470 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 28 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 27 Nov 2013 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.